| 1 | Lifestyle Profiles of Italian Oncology Nurses according to Sex, Work Experience and Shift: An Exploratory Study | 2.8 | 1 | Citations (PDF) |
| 2 | Associations between “Cancer Risk”, “Inflammation” and “Metabolic Syndrome”: A Scoping Review | 2.9 | 68 | Citations (PDF) |
| 3 | Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis | 4.0 | 145 | Citations (PDF) |
| 4 | Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications | 4.5 | 15 | Citations (PDF) |
| 5 | Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project | 3.3 | 4 | Citations (PDF) |
| 6 | Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes | 2.4 | 6 | Citations (PDF) |
| 7 | Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications | 4.0 | 9 | Citations (PDF) |
| 8 | Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis | 4.0 | 136 | Citations (PDF) |
| 9 | Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari | 3.1 | 2 | Citations (PDF) |
| 10 | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis | 3.1 | 7 | Citations (PDF) |
| 11 | Bayesian analysis supports the role of alectinib and ensartinib for
<scp>ALK</scp>
‐positive non–small cell lung cancer | 2.0 | 0 | Citations (PDF) |
| 12 | Hypertransaminasemia in Metastatic Renal Cell Carcinoma Patients Receiving Immune-Based Combinations: A Meta-Analysis | 2.1 | 3 | Citations (PDF) |
| 13 | Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials | 2.0 | 6 | Citations (PDF) |
| 14 | A Machine Learning Approach for Predicting Capsular Contracture after Postmastectomy Radiotherapy in Breast Cancer Patients | 2.3 | 5 | Citations (PDF) |
| 15 | Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues | 4.0 | 8 | Citations (PDF) |
| 16 | Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles | 4.8 | 11 | Citations (PDF) |
| 17 | The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma | 3.1 | 2 | Citations (PDF) |
| 18 | Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis | 1.8 | 4 | Citations (PDF) |
| 19 | Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2‐positive breast cancer patients: A machine learning approach | 2.7 | 5 | Citations (PDF) |
| 20 | Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis | 3.6 | 75 | Citations (PDF) |
| 21 | Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials | 3.6 | 80 | Citations (PDF) |
| 22 | PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? | 4.0 | 92 | Citations (PDF) |
| 23 | Microbiota and prostate cancer | 14.1 | 92 | Citations (PDF) |
| 24 | Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects | 4.0 | 81 | Citations (PDF) |
| 25 | Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond | 4.0 | 124 | Citations (PDF) |
| 26 | Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | 4.0 | 85 | Citations (PDF) |
| 27 | Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future | 3.1 | 8 | Citations (PDF) |
| 28 | Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first‐line treatment for advanced non‐small cell lung cancer | 2.0 | 1 | Citations (PDF) |
| 29 | Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis | 2.4 | 16 | Citations (PDF) |
| 30 | Dual Immune Checkpoint Blockade in Hepatocellular Carcinoma: Where do we Stand? | 2.4 | 6 | Citations (PDF) |
| 31 | Risk of Toxicity with Immunotherapy–Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials | 2.4 | 9 | Citations (PDF) |
| 32 | Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis | 2.6 | 3 | Citations (PDF) |
| 33 | Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors | 3.6 | 32 | Citations (PDF) |
| 34 | Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison | 2.4 | 7 | Citations (PDF) |
| 35 | Radiofrequency ablation, radiation therapy, transarterial chemoembolization, and yttrium 90: no differences for local treatment of liver cancer? | 1.8 | 3 | Citations (PDF) |
| 36 | Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis | 4.0 | 88 | Citations (PDF) |
| 37 | KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer | 2.4 | 85 | Citations (PDF) |
| 38 | Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis | 2.1 | 3 | Citations (PDF) |
| 39 | Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? | 2.5 | 75 | Citations (PDF) |
| 40 | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study | 4.0 | 5 | Citations (PDF) |
| 41 | Genomics and Immunomics in the Treatment of Urothelial Carcinoma | 3.1 | 9 | Citations (PDF) |
| 42 | Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | 4.0 | 93 | Citations (PDF) |
| 43 | Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer | 4.0 | 3 | Citations (PDF) |
| 44 | The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis | 2.6 | 14 | Citations (PDF) |
| 45 | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis | 4.8 | 19 | Citations (PDF) |
| 46 | Letter re: “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis” | 5.1 | 0 | Citations (PDF) |
| 47 | Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center | 3.1 | 5 | Citations (PDF) |
| 48 | Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis | 2.6 | 5 | Citations (PDF) |
| 49 | Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis | 2.6 | 9 | Citations (PDF) |
| 50 | Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer | 2.0 | 2 | Citations (PDF) |
| 51 | Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine | 3.7 | 21 | Citations (PDF) |
| 52 | Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | 4.0 | 26 | Citations (PDF) |
| 53 | Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma | 3.5 | 2 | Citations (PDF) |
| 54 | Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis | 5.1 | 144 | Citations (PDF) |
| 55 | Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study | 2.2 | 5 | Citations (PDF) |
| 56 | The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges | 2.2 | 7 | Citations (PDF) |
| 57 | Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives | 4.0 | 84 | Citations (PDF) |
| 58 | Recent advances of immunotherapy for biliary tract cancer | 2.5 | 111 | Citations (PDF) |
| 59 | Experimental HER2- targeted therapies for biliary tract cancer | 4.0 | 13 | Citations (PDF) |
| 60 | Immortal Time Bias in the Association Between Toxicity and Response for Immune Checkpoint Inhibitors: A Meta-Analysis | 2.1 | 120 | Citations (PDF) |
| 61 | Nivolumab: an investigational agent for the treatment of biliary tract cancer | 4.0 | 9 | Citations (PDF) |
| 62 | BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care | 2.5 | 66 | Citations (PDF) |
| 63 | Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma | 1.8 | 83 | Citations (PDF) |
| 64 | First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” | 1.8 | 71 | Citations (PDF) |
| 65 | Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review | 1.8 | 76 | Citations (PDF) |
| 66 | Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma | 1.8 | 63 | Citations (PDF) |
| 67 | Targeted therapy in <i>SDH-</i>deficient GIST | 3.8 | 33 | Citations (PDF) |
| 68 | PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer | 4.0 | 243 | Citations (PDF) |
| 69 | In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)” | 3.5 | 6 | Citations (PDF) |
| 70 | Treating Prostate Cancer by Antibody–Drug Conjugates | 4.5 | 87 | Citations (PDF) |
| 71 | Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer | 2.5 | 77 | Citations (PDF) |
| 72 | Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors | 2.6 | 22 | Citations (PDF) |
| 73 | Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing | 3.0 | 5 | Citations (PDF) |
| 74 | Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer | 4.0 | 91 | Citations (PDF) |
| 75 | TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review | 1.3 | 11 | Citations (PDF) |
| 76 | FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue | 2.5 | 9 | Citations (PDF) |
| 77 | Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience | 3.0 | 3 | Citations (PDF) |
| 78 | Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? | 0.9 | 0 | Citations (PDF) |
| 79 | Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications | 4.5 | 142 | Citations (PDF) |
| 80 | Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors | 2.2 | 13 | Citations (PDF) |
| 81 | Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait | 2.1 | 77 | Citations (PDF) |
| 82 | Comparative Effectiveness of First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors According to IMDC Risk Groups in Metastatic Renal Cell Carcinoma: A Meta-Analysis | 2.1 | 5 | Citations (PDF) |
| 83 | Determinants of Treatment for First-Line Immune-Based Combinations in Metastatic Renal Cell Carcinoma: a Critical Overview of Recent Evidence | 2.1 | 8 | Citations (PDF) |
| 84 | The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory? | 4.5 | 32 | Citations (PDF) |
| 85 | Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials | 3.0 | 14 | Citations (PDF) |
| 86 | Quality of Life Assessment in Renal Cell Carcinoma Phase II and III Clinical Trials Published between 2010 and 2020: a Systematic Review | 2.4 | 29 | Citations (PDF) |
| 87 | Hacking Pancreatic Cancer: Present and Future of Personalized Medicine | 4.4 | 49 | Citations (PDF) |
| 88 | An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma | 2.2 | 4 | Citations (PDF) |
| 89 | Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials | 5.1 | 88 | Citations (PDF) |
| 90 | Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges | 3.1 | 59 | Citations (PDF) |
| 91 | IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? | 1.8 | 27 | Citations (PDF) |
| 92 | Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report | 1.8 | 3 | Citations (PDF) |
| 93 | Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions | 1.8 | 14 | Citations (PDF) |
| 94 | Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al. | 3.7 | 0 | Citations (PDF) |
| 95 | An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT | 4.5 | 24 | Citations (PDF) |
| 96 | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? | 2.7 | 93 | Citations (PDF) |
| 97 | Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma | 3.3 | 73 | Citations (PDF) |
| 98 | Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis | 2.4 | 71 | Citations (PDF) |
| 99 | Regarding “HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer” | 3.5 | 5 | Citations (PDF) |
| 100 | Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos | 0.6 | 16 | Citations (PDF) |
| 101 | Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | 5.2 | 124 | Citations (PDF) |
| 102 | Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis | 3.8 | 93 | Citations (PDF) |
| 103 | Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors | 2.6 | 15 | Citations (PDF) |
| 104 | Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis | 4.0 | 50 | Citations (PDF) |
| 105 | Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile | 4.0 | 81 | Citations (PDF) |
| 106 | Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives | 1.7 | 94 | Citations (PDF) |
| 107 | PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? | 1.8 | 30 | Citations (PDF) |
| 108 | Is There a Role for Immunotherapy in Prostate Cancer? | 4.8 | 79 | Citations (PDF) |
| 109 | Evolution of the Experimental Models of Cholangiocarcinoma | 4.0 | 92 | Citations (PDF) |
| 110 | Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures | 4.0 | 11 | Citations (PDF) |
| 111 | The (Eternal) Debate on Microwave Ablation <i>Versus</i> Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma | 1.3 | 16 | Citations (PDF) |
| 112 | Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience | 2.6 | 68 | Citations (PDF) |
| 113 | Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions | 2.6 | 18 | Citations (PDF) |
| 114 | Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow | 1.2 | 73 | Citations (PDF) |
| 115 | Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma | 4.0 | 89 | Citations (PDF) |
| 116 | Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art | 1.2 | 34 | Citations (PDF) |
| 117 | How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis | 1.3 | 35 | Citations (PDF) |
| 118 | Specific Toxicity of Maintenance Olaparib <i>Versus</i> Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis | 1.2 | 26 | Citations (PDF) |
| 119 | Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis | 1.3 | 78 | Citations (PDF) |
| 120 | Pancreatic mucinous cystadenocarcinoma in a patient harbouring <i>BRCA1</i> germline mutation effectively treated with olaparib: A case report | 2.2 | 3 | Citations (PDF) |
| 121 | Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges | 2.4 | 33 | Citations (PDF) |
| 122 | Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman | 0.3 | 4 | Citations (PDF) |
| 123 | Current status of the adjuvant therapy in uterine sarcoma: A literature review | 1.1 | 60 | Citations (PDF) |
| 124 | Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept | 3.5 | 94 | Citations (PDF) |
